Kapszewicz Monika, Małecka-Wojciesko Ewa
Department of Digestive Tract Diseases, Medical University of Lodz, Kopcinskiego 22, 90-153 Lodz, Poland.
J Clin Med. 2021 Nov 22;10(22):5463. doi: 10.3390/jcm10225463.
A poor PDAC prognosis is due to a lack of effective treatment and late diagnosis. The early detection of PDAC could significantly decrease mortality and save lives. Idealbiomarkers for PDAC should be cost-effective, detectable in easily accessible biological material, and present in sufficient concentration in the earliest possible phase of the disease. This review addresses newly selected, simple protein biomarkers-new ones such as thrombospondin-2, insulin-linked binding protein 2, lysophosphatidic acid, and autotaxin and conventional ones such as Ca19-9, inflammatory factors, and coagulation factors. Their possible use in the early detection of PDAC, differentiation from benign diseases, prognosis, and treatment response prediction is discussed. We also address the usefulness of possible combinations of biomarkers in diagnostic panels.
胰腺导管腺癌(PDAC)预后较差是由于缺乏有效的治疗方法以及诊断较晚。早期检测PDAC可显著降低死亡率并挽救生命。理想的PDAC生物标志物应具有成本效益,可在易于获取的生物材料中检测到,并且在疾病的最早阶段以足够的浓度存在。本综述探讨了新选择的、简单的蛋白质生物标志物——新的如血小板反应蛋白-2、胰岛素连接结合蛋白2、溶血磷脂酸和自分泌运动因子,以及传统的如Ca19-9、炎症因子和凝血因子。讨论了它们在PDAC早期检测、与良性疾病鉴别、预后及治疗反应预测中的可能用途。我们还探讨了生物标志物在诊断组套中可能组合的有用性。